Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 1/2 5Phase 1 4Phase 3 2

Status

Recruiting 2

Sponsor Class

INDUSTRY 8OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Neoplasm Metastasis 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Disease Progression 1Breast Neoplasms 1

Interventions

Cisplatin 294Radiotherapy 230Fluorouracil 201Cyclophosphamide 191Capecitabine 183Docetaxel 167Gemcitabine 165Oxaliplatin 162Carboplatin 161Paclitaxel 152Leucovorin 122Drug Therapy 119Dexamethasone 119Doxorubicin 112Etoposide 99Bevacizumab 91Cytarabine 87Vincristine 83Irinotecan 81Rituximab 77Epirubicin 71Prednisone 65Radiosurgery 63Methotrexate 62Surgical Procedures, Operative 61Radiation 60Radiotherapy, Intensity-Modulated 57Neoadjuvant Therapy 53Lenalidomide 52Letrozole 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × OTHER × capivasertib × Clear all
NCT07281833 2026-02-27

CAPIcorn

West German Study Group

Phase 3 Recruiting
250 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Disease Progression

NCT03903835 2025-04-09

ProBio

Karolinska Institutet

Phase 3 Recruiting
750 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡